Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Post-marketing, Non-interventional Study of RISankizumab Evaluating Real-world Clinical Effectiveness in Crohn's Disease (APPRISE)

NCT05841537 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT05841537
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05841537 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Post-marketing, Non-interventional Study of RISankizumab Evaluating Real-world Clinical Effectiveness in Crohn's Disease (APPRISE)
Lead sponsor
AbbVie
Phase
Observational
Overall status
Active, not recruiting
Start date
June 9, 2023
Completion date
July 31, 2028
Enrollment
1,019 (actual)
Sites
154

Conditions

As the registry lists them; a condition with its own page is linked.

crohn's disease